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1. Introduction 
This chapter explores the interaction between melanoma and psychiatric disorder, updating 
our work with another decade of population-based data. Although psychiatric and physical 
disorders, such as melanoma, frequently co-exist, the relationship between the two may be 
complex. Psychiatric complaints may be secondary to physical illness, may cause or 
exacerbate physical symptoms, or the two may merely occur by chance in the same 
individual. When psychiatric disorder is secondary to cancer, it can be due to cancer-related 
factors, cancer-treatment-related factors, psychiatric history factors and social factors.1 
Melanoma is no exception to this. This chapter examines some of these possible interactions.  
2. Neuropsychiatric complications of interventions used to treat melanoma 
One obvious association between melanoma and psychiatric disorders is that many of the 
medications used to treat melanoma have psychiatric complications. A significant 
proportion of patients diagnosed with any form of cancer experience psychiatric morbidity 
in association with diagnosis and treatment. Factors that influence or increase the risk of 
psychiatric co-morbidity can be categorised as cancer-related factors, cancer-treatment-
related factors, psychiatric history factors and social factors.1 When we say that an 
intervention is a cause of an adverse health outcome we mean that it is a contributory cause 
of that outcome in the sense that use of that intervention is one of a complex set of 
conditions that jointly produced it.2 In order to infer that the intervention is a contributory 
cause we need evidence that: (1) medicine use and the health outcome co‐vary; and (2) 
evidence that other explanations of the relationship are   implausible, leaving medicine use 
as the most plausible explanation of the adverse health outcome.2 However, it can often be 
difficult to attribute a particular psychiatric state to a specific cancer treatment/intervention. 
It is recognised that a range of cancer treatments can contribute to the development of 
psychiatric disorders in cancer patients. Disease modifying agents such as corticosteroids, 
chemotherapeutic agents (vincristine, vinblastine, asparaginase, intrathecal methotrexate, 
interferon, interleukin, amphotericin) and whole-brain radiation have all been associated 
with the development of depression, delirium or dementia. In addition, treatment of pain 
with high-dose opioids can be associated with acute confusional states (delirium), 
particularly in the elderly and terminally ill.1  
There has been increasing concern about the psychiatric side effects of treatment with 
interferon (IFN), a therapy commonly used in the treatment of melanoma. Effects can occur 
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shortly after beginning IFN therapy or later as a consequence of sustained treatment.3 
Neurologic and neuropsychiatric complications include headaches, visual changes, 
paresthesias, hyperkinesia, decreased attention and concentration, and impairments in 
visual scanning, verbal memory, executive function, and motor control. Psychiatric 
complications include depression, anxiety, mania, and suicidal ideation. More rarely, IFN 
may induce mixed affective states in patients with melanoma with both depressive and 
manic symptoms. Patients are at particular risk of developing hypomania or mania when 
IFN doses are changed or when IFN-induced depression is treated with antidepressants 
without concomitant mood stabilisers. The risk of mood fluctuation continues after 
treatment with IFN stops. Greenburg et al reported that 40% of interferon-treated melanoma 
patients reported depressed mood and 8% reported severe depression with functional 
impairment or suicidal ideation.4 Adverse events following IFN treatment also include 
attempted and completed suicides.3  
Neuropsychiatric effects of IFN resulting in depression and/or anxiety may be mistaken by 
clinicians as representing the flu-like syndrome of IFN treatment, or as a reaction to the 
trauma of the cancer diagnosis. It is important that clinicians are able to recognise the 
treatment related psychiatric side effects of IFN and other interventions used to treat 
melanoma. 
3. The incidence and mortality of melanoma in people with psychiatric 
disorder  
This chapter focuses on another interaction, the incidence and mortality of melanoma in 
people with psychiatric disorder. Studies of overall cancer incidence and mortality in 
psychiatric patients have had mixed results. Some authors have reported lower than 
expected cancer incidence or mortality in psychiatric patients, whilst others have found no 
association.5-7 Still others have found an increased risk of incidence or mortality.8, 9 Some of 
this discrepancy may be explained by differences between psychiatric diagnoses. 
Schizophrenia has particularly been associated with a reduced incidence of cancer, 
including melanoma.10-15 The possible reasons for this are discussed in section 3.4. The use 
of different methodologies and cancer outcomes may also account for some of the 
conflicting results. For instance, some studies are restricted to patients in hospital.16 The 
reporting of cohort age at study conclusion may be an additional critical confounder. 
Populations where patients are not followed up to an age when cancer incidence and 
mortality is maximal may underestimate cancer mortality and incidence, making SMRs 
complex to interpret. Finally, cancer mortality may not be an ideal marker of the risk of 
cancer as it is affected by both the susceptibility to developing the disorder, and subsequent 
survival rates.17 
Our population-based studies from Western Australia and Nova Scotia addressed some of 
these issues by evaluating both the incidence and mortality associated with melanoma at the 
same time in the same population using a standard methodology.18 The studies used the 
administrative databases of each jurisdiction, which have several advantages over 
community surveys or data derived from individual clinical settings19, in that they provide 
accessible longitudinal data for an entire jurisdiction at relatively little cost. In both, rates 
were calculated using the inception cohort method.20 The start of follow-up was taken as the 
date of each patient's first contact with mental health services. Patients were censored at the 
time of occurrence of the event under study, death, or the end of follow-up. The cohort was 
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limited to people whose first contact with a clinician occurred in the study period, excluding 
people whose first contact occurred prior to the start of follow-up. This avoids the 
possibility of survivorship bias, which could otherwise occur if cancer risk changes with 
time since first contact with a clinician. After reviewing our previous work from Western 
Australia and Nova Scotia, we present another decade of Australian data to further explore 
these relationships through to 2007. 
3.1 The psychiatric disorders of interest 
The psychiatric disorders that form the focus of this chapter include all the mental and 
behavioural conditions covered in Chapter 5 of ICD9 (290 through 319 inclusive), or ICD10 
chapter F. These capture organic psychiatric disorders such as dementia, alcohol and 
substance use disorders, psychosis, non-psychotic diagnoses including depression, anxiety, 
and somatoform conditions, and personality and adjustment disorders. Some of the studies 
also capture ICD external cause codes X60 – X84 (Intentional Self Harm) and non-Chapter 5 
codes that cover health service use for mental health issues in the absence of a formal 
psychiatric diagnosis.  
3.2 The Western Australia study 1982-1998 
Within the WA Health Services Research Linked Database, we identified all psychiatric 
patients in Western Australia who had a diagnosis of cancer. The dataset contains 
information from several different core data sets. These were the Hospital Morbidity Data 
System (HMDS), the register of births, the register of deaths, Mental Health Information 
System, and the Cancer Registry. The Mental Health Information System (MHIS) is a 
register of patients who have had contact with state run community-based or outpatient 
mental health services in WA or who have been psychiatric inpatients of any public or 
private hospital in the state since 1966. Although the MHIS has been operating since 1966, 
the WA Cancer Register only commenced in 1982. Thus the linked cancer registrations 
covered the period 1982 to 1998. Diagnoses were coded according to ICD-8 until 1978 and 
according to ICD-9 from 1979 onwards. The last occurring psychiatric diagnosis across the 
episodes was then assigned as the principal diagnosis according to a hierarchy of diagnoses. 
If an earlier diagnosis was higher in the hierarchy than the last recorded diagnosis, then the 
earlier diagnosis was taken as the principal diagnosis. The hierarchy was as follows: 
i. ICD-9 290, 293±296: dementia, organic psychotic conditions, schizophrenia and affective 
psychosis. 
ii. ICD-9 291±292, 297±305, 313±315: alcohol and drug psychoses, paranoid states, other 
nonorganic psychoses, neurotic disorders, personality disorders, sexual deviations, 
alcohol and drug dependence, and childhood disorders. 
iii. ICD-9 306±312, 317±319: adjustment reaction, reaction to stress, depressive disorders 
nec1, conduct disorders nec, special syndromes nec and mental retardation. 
iv. Other than chapter 5 (mental disorders) diagnoses. 
Preference was given to diagnoses made in inpatient treatment units over diagnoses made 
in acute inpatient units or longer-term psychiatric residential units. Diagnoses made prior to 
1979 were mapped from ICD-8 to ICD-9 using the nearest equivalent code. The purpose of 
these procedures was to allow more specific psychiatric diagnoses to take precedence over 
less specific diagnoses, and to favour an underlying condition rather than a non-specific 
                                                 
1 Not elsewhere classified 
www.intechopen.com
 
Melanoma in the Clinic – Diagnosis, Management and Complications of Malignancy 
 
290 
symptom or event. Cancers were classified according to the ICD-9 classification of diseases 
at the three-digit level. This classification followed the same system used for classifying 
cancers by the WA Cancer Register.  
Overall there were 672 melanoma patients, of whom 285 were male (Table 1). Males were 
significantly less likely to be diagnosed as having a melanoma while females had the same 
rate as that of the general population. There was little variation between psychiatric 
diagnoses although conclusions were limited by the small number of cases for some of the 
categories (Table 1). In no case was incidence higher than that of the general population 
(Table 1). 
Proportional hazards regression analysis was used to examine the difference in case fatality 
between psychiatric patients with cancer and other cancer patients in the general 
population. After adjusting for demographic factors, there was a 103%  higher case fatality 
following a diagnosis of melanoma in male psychiatric patients than in the general 
population (95% CI: 46% - 282%) and an 89% higher case fatality rate in females (95% CI: 
43%-274%). This represented the  highest case fatality rate ratios  for any cancer site.  
 
Psychiatric diagnosis 
Male Female 
N RR 95% CI RR 95% CI 
Dementia 12 0.67 (0.19 -2.45) 9 0.47 (0.02 – 14.5) 
Alcohol/drug disorders 35 0.41 (0.18 -0.94) 12 0.46 (0.13 - 1.59) 
Schizophrenia 22 0.76 (0.42 - 1.38) 20 0.93 (0.50 - 1.71) 
Affective psychosis 19 0.70 (0.33 - 1.49) 43 1.06 (0.73 - 1.54) 
Other psychoses 6 0.62 (0.15 -2.54) 12 0.49 (0.14 – 1.71) 
Neurotic disorders 67 0.99 (0.76 - 1.30) 129 1.10 (0.91 - 1.33) 
Personality disorders 20 1.29 (0.85 - 1.95) 15 1.26 (0.76 – 2.10) 
Stress/Adjustment 
reaction 
8 0.46 (0.09 - 2.37) 24 0.78 (0.45 - 1.38) 
Depressive disorder 8 0.61 (0.19 - 1.93) 21 0.99 (0.57 - 1.70) 
Other mental disorder 31 0.79 (0.48 - 1.30) 26 0.72 (0.38 - 1.34) 
Attempted self-harm 14 0.68 (0.29 - 1.61) 26 1.14 (0.76 – 1.70) 
Non-specific diagnosis 43 1.11 (0.84 - 1.46) 50 0.85 (0.60 - 1.21) 
Total 285 0.75 (0.64 - 0.89) 387 0.92 (0.82 – 1.04) 
Table 1. Cancer Site - Malignant Melanoma, by Principal Psychiatric Diagnosis. WA 1982 – 
1998. 
3.3 The Nova Scotian study  
The West Australian administrative data do not include treatment for mental health 
disorders in private settings. Accordingly, studies from Australia, where both private health 
insurance and hospitals play a sizable role in providing medically necessary care, may not 
apply to jurisdictions such as Canada with universal health care provision. We therefore 
compared cancer incidence, first admission and mortality rates for people with psychiatric 
disorder in relation to the general population of one Canadian province, Nova Scotia. In 
addition, the Australian data were restricted to people in contact with specialist mental 
health services and did not include primary care where the majority of people with mental 
health problems are treated. Lastly Canadian data allowed for the study of patterns of 
melanoma in a less sunny environment.  
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Under the Canada Health Act, all Canadian residents are entitled to inpatient or outpatient 
care that is free at the point of delivery.21 Patients receive treatment at publicly -funded 
facilities or are seen by private psychiatrists or general practitioners in the community who 
bill the Provincial health plan. However, the Provincial health plan does not cover visits to 
private psychologists or other mental health professionals in private practice. Importantly, 
there are no private psychiatric beds.21 
We evaluated the association between mortality and psychiatric disorder for all patients of 
specialist services and primary care across Nova Scotia, using the province’s linked 
administrative databases. The one-million residents have similar morbidity and mortality 
rates to the rest of Canada, although more live in rural areas than in other provinces. Halifax 
is the major metropolitan centre. 
We evaluated the association between cancer mortality and psychiatric disorder for all 
patients of specialist services and primary care across Nova Scotia. We used the following 
Provincial administrative databases, held at the Population Health Research Unit (PHRU) of 
Dalhousie University, to identify anyone in contact with health services for psychiatric 
problems:22 
 The Medical Services Insurance (MSI) database of all fee-for-service claims by 
physicians including patient demographics, date of service and diagnosis from the 
Clinical Modification of the 9th Revision of the International Classification of Diseases 
(ICD-9-CM). This includes family physicians and psychiatrists.  
 The Canadian Institute for Health Information (CIHI) Discharge Abstract Database 
(DAD), which includes admissions, separation dates, diagnoses and procedures. 
 Mental Health Outpatient Information System data (MHOIS), which records service 
contacts, demographics and diagnoses in the public sector. This includes contacts with 
all mental health clinicians, not just physicians. 
This method was consistent with the definition used by the Public Health Agency of Canada 
(PHAC) for the surveillance of treated psychiatric disorder.19, 23 As in Western Australia, we 
used an inception cohort. We included patients whose first psychiatric contact with primary 
or specialist services occurred between January 1, 1995 and December 31, 2001, and linked 
data using the provincial health card number as a unique identifier. Health card numbers 
are present in over 99% of records irrespective of database, and encrypted to ensure 
confidentiality. 
We included everyone with ICD 9 codes of 290 through 319 inclusive, or their ICD-10 
(chapter F) or DSM-IV equivalents.  We also included non-specific mental disorders outside 
Chapter 5 of ICD-9 (formal mental disorders), such as injury of undetermined intention or 
psychosocial factors influencing health status, to ensure comparability with previous 
Australian work.17 We did not include non-chapter 5 diagnoses of primary care patients, as 
they would not necessarily be psychiatric. We included contacts with primary or specialist 
services. We used a hierarchy of inpatient versus outpatient, and specialist versus primary 
care, reflecting both the increasing percentage of patients with severe mental illness and 
data reliability. It also allowed comparison with Australian data  
We then transferred this data file to Cancer Care Nova Scotia who linked it to the Nova 
Scotia Cancer Registry (NSCR) to identify cancer incidence rates for the cohort. The NSCR 
has population-based incidence data that dates from 1964.28 All malignant and in-situ 
tumours are reportable by law within the province. Other sources of data include Pathology 
Reports (1982 onwards) and death certificate information for all provincial deaths (from 
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1989 onwards). Registry operations meet the consensus on cancer registration standards 
outlined by both the Canadian Cancer Registry (CCR) and the North American Association 
of Central Cancer Registries (NAACCR).18 The NSCR works collaboratively with Statistics 
Canada to ensure that Nova Scotia data is part of the national Canadian Cancer Registry. 
We classified cancers according to the ICD-9 classification of diseases at the three-digit level. 
This classification followed the same system used for classifying cancers by the NSCR. The 
cancer sites selected for analysis were the most frequent cancers in males and females. 
We grouped disorders into dementia and other organic conditions (290-294), schizophrenia 
(295), other non-affective psychoses (297, 298.0, 298.1), alcohol/drug disorders (303-305), 
mood disorders (affective psychoses/depression-296, 298.2-298.9, 300.4, 311), neuroses (300 
except 300.4), personality disorders (301), adjustment reactions (308-309), and other mental 
disorders (all remaining Chapter 5 diagnoses and those outside Chapter 5). Rates were again 
calculated using the inception cohort method.20 The start of follow-up was taken as the date 
of each patient's first contact with a mental health clinician. Patients were censored at the 
time of occurrence of the event under study, death, or 31st December 2001. The cohort was 
limited to people whose first contact with a mental health clinician occurred in the study 
period, excluding people whose first contact occurred prior to the start of follow-up. We 
derived mortality rates from the Statistics Canada Vital Statistics Database. Person-years at 
risk were calculated separately for each outcome.  
We calculated  age- and sex-adjusted mortality, first admission and incidence  rates for 
carcinoma by direct standardisation, using the average population distributions in Nova 
Scotia from 1995-2001 inclusive as the standard weights. We then calculated rate ratios (RRs) 
relative to the rate in the general NS population, using 95% confidence intervals to test for 
significance. Variance of the standardised rate ratios was calculated using expansion in 
Taylor series, using a logarithmic transformation of the ratio.24 We assessed whether the rate 
ratios for mortality, first admission and incidence in psychiatric patients were significantly 
different from the general population of Nova Scotia as indicated by 95% confidence 
intervals that included a value of 1.0. We also assessed whether there were differences 
between mortality, first admission and incidence rate ratios. Unlike the Australian study, we 
were not able to investigate predictors of cancer incidence using Cox regression of NSRC 
records because of the nature of the data sharing agreement and therefore were unable to 
compare adjusted hazard ratios for incidence, first admission and mortality.  
Table 2 presents the unadjusted rate ratios. Incidence rate ratios (RRs) were lower than 
might be expected given the mortality and first admission RRs, and no higher than that of 
the general population. By contrast the mortality rate was higher especially for men. 
 
Gender 
Mortality rate Cancer Incidence 
N RR 95% CI N RR 95% CI 
Males 17 2.18 (1.34-3.44) 151 1.05 (0.92-1.21) 
Females 3 1.37 (0.64-2.92) 99 0.91 (0.73-1.07) 
Total 20 2.00 (1.20 – 3.30) 250 0.98 (0.85-1.14) 
Table 2. Comparing Cancer Incidence and Cancer Mortality rates: Nova Scotia, 1995 – 2001. 
Melanoma was only one of a few cancers to show this pattern, the others being prostate, 
bladder and colorectal cancers. This pattern was especially noticeable in males (Figure 1). 
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Fig. 1. Comparing cancer mortality & incidence in male Nova Scotian psychiatric patients 
3.4 Implications of both studies 
There is a common assumption that problems in self-care might explain the increased 
mortality from cancer, including melanoma, for patients with psychiatric disorder. If that 
were the sole explanation, incidence would consistently reflect the increased mortality rate. 
However, our work in both Canada and Australia suggests that psychiatric patients are no 
more likely to develop melanoma than the general population but still have increased 
mortality for the same condition. There may be a number of explanations for this increased 
case fatality rate. One might be that psychiatric patients present later, and with more 
advanced disease, than the general population. Another possibility is reduced access to 
general medical care. If doctors are less inclined to treat skin cancer in people with 
psychiatric disorder than in others, people with psychiatric disorder and skin cancer might 
be less likely to be admitted to hospital and therefore be selectively missed by researchers. 
This inequity would be of concern, and would confirm work from Ontario showing that 
other marginalised populations, such as those of low income, are less likely to receive 
specialist procedures such as adjuvant or palliative radiotherapy.25  
Decreased screening for early lesions could also explain the increased mortality so that 
psychiatric patients only present when symptoms or signs become more obvious in later 
stages of the disease. In places without universal health care, ability to pay for care may be a 
factor. Even with universal health care, psychiatric patients may have problems in 
registering with a family physician, missed appointments, or difficulties in communication 
or scheduling appointments. Finally, psychiatric patients may have a worse prognosis even 
after adjusting for staging at presentation. Survival from cancer is associated with levels of 
depression, emotional expression and support. Some work suggests that individuals with 
depression prior to the diagnosis of the cancer have a worse survival rate than those with 
depression following diagnosis.26 In the case of melanoma, several psychosocial variables 
measured at baseline are independently prognostic of survival. 26 The greatest protective 
effect was conferred by a belief that treatment would lead to cure or long-term survival and 
by marital status. 26 For those patients who were positive about the outcome of their 
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treatment (i.e., who thought treatment would cure them or prolong their life long term), the 
risk of dying was reduced by 65%. Similarly, for patients who were married, the risk of 
dying was reduced by 50%. Two aspects of psychological adjustment were also protective. 
Patients who reported that their melanoma did not greatly affect their day-to-day life 
survived significantly longer than those who felt it was having a big impact on their lives, 
and those who exhibited greater levels of anger about their situation survived longer. 
Finally, quality of life scores were also significantly predictive of outcome. Further support 
for the importance of psychiatric factors in survival from melanoma comes from findings that 
structured group psychotherapy may help extend survival. 
3.5 The special case of schizophrenia 
In the case of schizophrenia, there is a suggestion that the incidence of skin cancer including 
melanoma is especially lower than the rest of the population. A Danish record linkage study 
investigated the incidence of cancer in a cohort of 9156 first admitted schizophrenic 
patients.13  Reduced cancer incidence was particularly marked for genital cancers, and skin 
cancers, including malignant melanoma. The standardised incidence ratio for malignant 
melanoma was 0.14, although the study was limited by small numbers (1 case of 
melanoma). Goldacre and colleagues reported a similar finding in a cohort analysis of 
linked hospital and death records comparing cancer rates in people with schizophrenia with 
a reference cohort in the south of England27. They reported an adjusted rate ratio for 
melanoma of 0.2 (95% CI 0.02-0.74). A recent meta-analysis of cancer incidence rates in 
patients with schizophrenia combined 16 data collections from 15 studies. The pooled 
standardised incidence rate ratio of melanoma in patients with schizophrenia was 
significantly reduced (SIR 0.71 CI 0.57-0.87). A similar finding was reported for prostate 
cancer.28 
Several biological hypotheses have been proposed to explain why people with 
schizophrenia might be protected against cancer in general, including a protective effect of 
excess dopamine, enhanced natural killer cell activity, an increase in the rate of apoptosis 
and modulation by antipsychotic drugs of the human cytochrome enzymes involved in 
mutagen activation and elimination27.  
There may be other reasons that are more specific to melanoma. One possibility is that 
people with schizophrenia may spend less time in the sun than the general population, and 
this may be compounded by issues such as weight gain (a common side effect of anti-
psychotic medication) that may reduce both the desire and ability to engage in physical 
activity outdoors. Conversely if they do go out into the sun, people with schizophrenia 
might be less likely to take protective measures such as sunscreen or a hat. Against this 
explanation is that malignant melanoma is mainly related to childhood sun exposure,29 and 
there is no evidence of reduced childhood sun exposure in individuals who subsequently 
develop schizophrenia. 
In addition, sun exposure, perhaps through its role in vitamin D synthesis, may actually 
have a protective role in the development of schizophrenia. 30 McGrath has suggested that 
vitamin D deficiency in the neonate might be a risk factor for the subsequent development 
of schizophrenia. The same author also suggested that relative vitamin D deficiency might 
explain some of the  epidemiological features of schizophrenia such as the excess of winter 
births, and the increased incidence of schizophrenia in dark-skinned migrants when they 
move to countries with more limited sunshine31. It is therefore possible that an inverse 
relationship between sun exposure and the development of schizophrenia could also 
partially explain why melanoma is seen less frequently in people with schizophrenia.  
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4. Our latest findings 
We extended our work with another decade of data from Western Australia to further 
explore these relationships through to 2007. As before we used the linked administrative 
data from Western Australia from 1988 to 2007 employing the same databases. We also 
extended our study to the Australian State of Queensland, which has the highest rate of 
melanoma in Australia. On this occasion we investigated whether the pattern of psychiatric 
patients being  no more likely to develop melanoma than the general population, but still 
having  increased mortality for the same condition could be related to either: 
1. delayed diagnosis or late presentation by comparing cancer staging at the time of 
diagnosis in psychiatric patients & the general population as determined by the 
presence of metastases; or   
2. reduced access to specialised cancer therapy such as chemotherapy, radiotherapy and 
surgery once the diagnosis has been made. 
If the former were true, it would indicate that specific action is required to ensure that 
clinicians and patients themselves consider the diagnosis of cancer in response to new 
symptoms, and that psychiatric patients are encouraged by their GP to attend, and are able 
to access appropriate routine cancer screening services. If the second were true it would 
indicate inequity of access to surgery, and adjuvant or palliative radio- and chemotherapy. 
To investigate the first question, we calculated the proportion of patients with metastases at 
diagnosis, as melanoma staging is not collected in the cancer registry in WA. This was 
undertaken by extracting the behaviour code, which forms the end digit of the morphology 
code, a code that must be provided should a neoplasm ICD10 code be recorded (C00 – C96, 
D00 – D48). Behaviour code /6 refers to a malignant neoplasm that is stated or presumed to 
be secondary so a morphology code of M8720/6 refers to melanoma that is stated or 
presumed to be secondary. Also ICD10 code C80 is a malignant neoplasm of unknown 
primary origin; these have also been extracted to represent secondary cancers at diagnosis. 
In Queensland, the cancer registry does collect data on melanoma staging based on Clark’s 
level, thickness and ulceration but it is impossible to determine when the cancer 
metastasised. Data on the time of metastasis were therefore extracted from hospital 
admissions using ICD10 codes C77 – C79, which are the particular ICD10 codes for a 
secondary cancer site. We also measured the proportion of patients developing metastases 
at 90 days and one year after presentation.  
To investigate the second question, we collected basic information on cancer treatment, 
including chemotherapy (yes/no), radiotherapy (yes/no) and surgery (yes/no). For surgery 
we also collected information on time to surgery from diagnosis. For palliative care we 
assessed the proportion of cases that had at least one course of palliative radiotherapy (PRT) 
in the last 2 years of life. This measure has been used elsewhere as a proxy for access to 
radiotherapy services.32 For surgery we collected information on time to surgery from 
diagnosis. We used the method of Valery, Coory et al in their studies of cancer services in 
Indigenous Queenslanders to compare access to chemotherapy, radiotherapy and surgery.23 
4.1 Aims 
The aims were to investigate the following: 
1. To compare the incidence and mortality of melanoma in psychiatric patients and the 
general population of Western Australia and Queensland from 1988 to 2007 (2002 to 
2007 in the case of Queensland)  and to determine whether there are significant 
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differences between types of psychiatric illness (e.g. schizophrenia, affective disorder) 
in incidence, and mortality rates. 
2. To determine whether psychiatric patients present at a more advanced stage of 
melanoma at diagnosis than the general population as determined by the presence of 
metastases and whether there is a difference in cancer stage at presentation between 
male and female psychiatric patients.  
3. To determine whether psychiatric patients have a poorer prognosis after controlling for 
cancer stage at presentation and whether there is a difference in prognosis between 
males and females. 
4. To determine whether psychiatric patients diagnosed with cancer access surgical 
services equally in comparison with the general population diagnosed with cancer, and 
whether there is a difference in access by gender. 
5. To determine whether psychiatric patients diagnosed with cancer access adjuvant or 
palliative chemotherapies & radiotherapies equally in comparison with the general 
population , and whether there is a difference by gender 
4.2 The hypotheses 
The hypotheses were that: 
1. Psychiatric patients would be more likely to present with more advanced cancer, as 
determined by the presence of metastases.  
2. Psychiatric patients would also be less likely to receive the appropriate specialist 
surgical procedures, adjuvant or palliative chemotherapies & radiotherapies than the 
general population, even after adjusting for socio-demographic and clinical features 
(including the presence of metastases).  
3. These effects would be more marked for patients with severe mental illnesses in terms 
of either diagnoses (e.g. schizophrenia) or of having ever required admission to a 
psychiatric unit, and more marked in men than women. 
4.3 Study design  
This was a population-based record-linkage analysis from the two Australian states 
(Western Australia and Queensland), using a historical cohort to calculate rate ratios. In the 
case of the Western Australian data we also calculated rate ratios using the inception cohort 
method. We could not do the same for the Queensland data as these did not extend far 
enough to identify an inception cohort. It is important to do both. Inception cohort studies 
that study incident psychiatric cases over a period of time are less subject to survivorship 
bias given that the majority of excess deaths due to physical causes occur in the first seven 
years after psychiatric diagnosis.17 However as they are based on incident cases, there may 
be fewer subjects than a study based on prevalence, and so a greater chance of insufficient 
statistical power. This is particularly relevant for less common outcomes such as mortality in 
individual psychiatric diagnoses that are less common such as schizophrenia. Using an 
inception cohort also allowed comparison with our previous studies from Western Australia 
and Canada. Historical cohorts are based on prevalent psychiatric cases and so yield larger 
numbers. They are therefore more appropriate for rarer outcomes. In this case, use of an 
historical cohort allowed the addition of Queensland data, so further increasing statistical 
power. On the other hand, historical cohorts may underestimate overall mortality risk 
because of survivorship bias.  
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4.4 Data sources  
The project used linked datasets provided by the data linkage centres of Queensland and 
Western Australia. Both form part of Australia’s Population Health Research Network 
(PHRN) (Figure 2). PHRN is a national network of Australia’s extensive health data that 
provides linkage across data sets in all States and Territories for population health research 
(Figure 2). Subject anonymity was preserved by a rigorous privacy protocol, as it was not 
possible to obtain informed consent given we were using large population datasets. In each 
case, the relevant data custodian provided demographic data, but no other information, to 
data linkage centres within the Health Department of each jurisdiction. Within the linkage 
centre, probabilistic and deterministic matching were used to link within and between the 
datasets based on identifying information (ID), including name, date of birth, aliases, sex, 
and Indigenous status. Each person was assigned a unique project ID that was returned to 
the data custodians. The data custodian attached the relevant clinical or service information 
to the unique project ID, but no identifying information. These anonymised data extracts 
were then released to the researchers. 
 
 
Fig. 2. Australia’s Population Health Research Network. 
4.4.1 Western Australia 
We identified users of mental health services in WA with cancer registrations and death 
records, using the WA Health Services Research Linked Database. In this database, 
individual patient records have been linked by means of probabilistic matching, using the 
Automatch software package,33 as there are no unique identification numbers in use on the 
core data sets. Name, residential address, date of birth and sex are the principal fields used 
in the probabilistic matching.20  The probabilistic matching technique is based on estimating 
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the probability that any two records represent the same person (or event), while allowing 
for the possibility of errors or changes in the identifying information used for matching.20 
The dataset contains information from several different core data sets. As before, we used 
the following: Hospital Morbidity Data System (HMDS), the register of births, the register of 
deaths, Mental Health Information System, and the Cancer Registry (Figure 3). The Mental 
Health Information System is a register of patients who have had contact with state run 
community-based or outpatient mental health services in WA or who have been psychiatric 
inpatients of any public or private hospital in the state.  
 
 
Fig. 3. Schema of the WA Health Services Research Linked Database 
Within the WA Health Services Research Linked Database, we identified all psychiatric 
patients in Western Australia who had a diagnosis of cancer. We  used  the same case 
definition for psychiatric disorder that has been validated by the Public Health Agency of 
Canada (PHAC) for use in administrative databases.23 This is any contact with a health 
service with an ICD-9 diagnosis of 290-319 or ICD10 equivalent. As stated previously, we 
used both the historical and inception cohort method. For the latter, we restricted the study 
cohort to those patients whose first contact with mental health services occurred between 
1988 and December 2007. The start of follow-up was the date of each patient's first contact 
with mental health services. 
Patients were censored at the occurrence of the event under study, death, or 31st 
December 2007. We compared the outcomes of this cohort to the general population 
through the calculation of age-, sex-standardised rates, which were then adjusted for 
confounders using multivariate analyses (see section 4.6 on statistical methods). 
Outcomes were mortality, metastases and access to surgery or radiotherapy. Data linkage 
of all administrative data, including epidemiological databases, was carried out by the 
Data Linkage Branch at the WA Department of Health which houses the Western 
Australian Health Linked Database. 
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4.4.2 Queensland 
We used a similar methodology in Queensland. We extracted data from the following 
datasets: the Queensland Hospital Admitted Patients’ Data Collection (QHAPDC), the 
Client Event Services Application (CESA – now called CIMHA, community integrated 
mental health application), Queensland Cancer Registry (including death data), 
BreastScreen QLD and the Australian Bureau of Statistics Estimated Resident Population 
(Table 3). As in Western Australia, we identified all psychiatric patients in Queensland with 
the diagnosis of cancer using the Public Health Agency of Canada (PHAC) case definition of 
psychiatric disorder. In this case, the Link King software package was used to link 
individual patient records probabilistically and deterministically.  
 
Data source Data obtained 
Queensland Hospital 
Admitted Patients’ Data 
Collection  
In-patients receiving treatment in a designated psychiatric 
unit in a public hospital or public psychiatric hospital in 
QLD; all cancer admissions in public & private hospitals 
and all co morbidity data in the twelve months prior to the 
cancer diagnosis (Charlson Deyo) 
Client Event Services 
Application (CESA)  
Clients receiving treatment in a public-sector community 
mental health service  
Queensland Cancer 
Registry 
All QLD cancer registrations, with details of diagnosis 
including date, ICD-10 site code, morphology code. Data 
on people who die of cancer or cancer patients who die of 
other diseases linked to mortality files of the Registrar of 
Births, Deaths & Marriages & linked to hospital & 
pathology data. 
BreastScreen QLD 
All voluntary screening records for patients subsequently 
diagnosed with breast cancer 
Australian Bureau of 
Statistics  
Estimated resident population for all of Queensland 
 
Table 3. Queensland data sources 
4.5 Data quality 
The WA Health Services Research Linked Database is unique in Australia and one of only a 
small number of comprehensive record linkage systems in the world.20 These include the 
Oxford Record Linkage Study, the Scottish Record Linkage System, the Rochester 
Epidemiology Project, the Manitoba Population Health Information System, the Nova 
Scotian linkable database system and the Scandinavian case registers. Probabilistic matching 
of records is based on estimating the probability that any two records represent the same 
person (or event), while allowing for the possibility of errors or changes in the identifying 
information used for matching. The WA Data Linkage System uses a chain of links method 
to map the linkage of records. Each individual source record from each of the component 
data sets is assigned a unique record number. Separate individuals are then identified by 
assigning a number to identify the chain, called the root number. This root number is the 
record number of the first record in the chain for each person. A master linkage file records 
pointers specifying the root number for each individual source record in the system, 
enabling chains of records for each individual to be created.  
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The master linkage file is date stamped and records the history of all updates to the system, 
so the state of the linkage can be reconstructed as it existed on any previous date.20 The 
construction of the WA Linked Database and its ongoing maintenance are performed by an 
extramural unit of the Centre for Health Services Research located within the Health 
Information Centre. Access to identifying information is restricted to the staff of the extra-
mural unit. Once the data have been linked, a second de-identified copy of the WA Linked 
Database is created. The de-identified version does not contain names, addresses (except for 
postcode), dates of birth (except for month and year of birth), individual hospital identifiers 
or individual doctor identifiers. Most research is conducted from this second de-identified 
copy of the database. The system allows for the protection of the confidentiality of 
individual patients and the information contained in the administrative health records, 
while still allowing population-based health services research to be performed. 
The WA Health Services Research Linked Database currently contains in excess of 12 million 
records, and occupies over 12 Gb of storage space. By far the largest component of the 
database is the Hospital Morbidity Data System (HMDS) which contains over 7 million 
records. The register of births contains around 400,000 entries, while the register of deaths 
contains approximately 450,000 entries. The MHIS contains details for just over 300,000 
patients of mental health services (Figure 3). As the WA Data Linkage System brings 
together separate records for each person, it is possible to examine the consistency of 
recording fixed personal characteristics such as sex, aboriginality, and date of birth. For each 
of these characteristics, the entire set of records for each patient have been examined to 
check that the field was recorded the same in all core data records regardless of their source. 
Overall, sex was consistently recorded across all records for 98.5% of the study population, 
aboriginality was consistently recorded for 97.3% of the study population and date of birth 
was consistently recorded (to an exact date) for 83.3% of the study population 
Data linkage in Queensland has not progressed as far as that in Western Australia since the 
state has only recently begun developing linkage infrastructure whereas WA began this 
process in 1995. There are a large number of databases available but currently linkages exist 
only within the Queensland Hospital Admitted Patient Data Collection (QHAPDC) for 
years 2003/04-2008/09 and between QHAPDC and the Registrar General’s (RG) Mortality 
data. RG mortality data is available from 1996 onward and contains approximately 360,000 
records. RG birth data (over 64,000 records in 2010) is also available but the exact dates that 
are available for research are yet to be determined and this collection hasn’t yet been linked 
with other databases. QHAPDC data collection began in January 1993 and on average there 
are about 1.8 million episodes of care added to the QHAPDC database each year. Episodes 
of care for admitted mental health patients are also captured within this database and a 
mental health module was added in July 1996. Non-admitted mental health patients that are 
seen by community mental health facilities are included in the Consumer Integrated Mental 
Health Application (CIMHA) database which, over a five year period (2006 – 2010), 
contained over 280,000 consumer (patient) records. 
There is also less information on the quality of the Queensland data as these datasets have 
only recently been used for research. Some published information is available on the quality 
of variables such as Indigenous status, which can be defined either through place of 
residence or through the recording of Indigenous status in datasets such as the Queensland 
Hospital Admitted Patient Data Collection (QHAPDC). Indigenous status is correctly 
identified in about 89% of cases with variation by definition used.34  
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4.6 Statistical methods 
We identified cancer type, cancer stage at diagnosis by cancer type, principle psychiatric 
diagnosis, and time from psychiatric contact with service until cancer incidence. We initially 
calculated the age- and sex-standardised mortality rate, cancer incidence and proportion 
with metastases at diagnosis for all cancers for anyone meeting the PHAC case definition of 
psychiatric disorder. We  used the method of Lawrence et al. to group cases in terms of 
severity of psychiatric diagnosis.20 We  also calculated separate age- and sex-standardised 
ratios for cases who had ever had inpatient psychiatric treatment as opposed to those who 
had only had outpatient treatment, as a marker of psychiatric disease severity. Finally we 
calculated rates of surgery, and adjuvant or palliative radio- and chemotherapy in the same 
way.  
The average population distribution in Western Australia over the period 1988-2007 was 
used as a standard weight. In all cases we used direct standardisation. Rates were calculated 
overall, and by principal psychiatric diagnosis. Relative risks for mortality, 1st admissions, 
incidence, and cancer stage for different cancer types  were calculated in groups of patients 
in the study cohort relative to the rate in the WA population. Denominators were taken from 
estimated resident population counts. We compared relative risks by psychiatric diagnosis, 
cancer type, diagnostic case complexity and treatment setting (ever admitted as an in-
patient versus outpatient or community care).  
The relative importance of factors that were identified on univariate analysis as being 
associated with the particular outcome under study (e.g. presence of metastases, mortality) 
were further analysed using the Cox proportional hazards model. This methodology 
requires the identification of a terminal event that marks either survivors or non-survivors. 
Consequently, there are two basic requirements for a survival analysis design- time of origin 
into the study and the meaning of failure. In our study, the former was entry into the study, 
and the failure was defined as mortality. One advantage of survival analysis is that it allows 
an examination of data from all participants who entered the study over the sampling 
timeframe (until the end of the study) without imposing arbitrary cut-off dates on the data. 
Participants who were still alive at the end of the study were treated as censored 
observations (i.e. an observation for which the event does not occur). Cox’s model allowed 
us to quantify the weight of or significance of variables that increased or decreased the risk 
of admission. Using the statistical technique of “backward elimination,” we  eliminated non-
significant variables from each group of variables sequentially in order to retain the relative 
risk of each significant variable. For longitudinal items (e.g. mortality), we included the 
presence of metastases, as well as all other relevant socio-demographic & clinical variables. 
Survival analysis is more appropriate than logistic regression for studying time to event 
data (e.g. time to mortality following cancer diagnosis) while logistic regression is useful in 
developing an initial model. 
4.7 Preliminary results 
We present initial results from the Western Australian arm of the study, as Queensland data 
are as yet unavailable. Because the results are confined to Western Australia, we have given 
greater prominence to the inception, as opposed to historical cohort although we present the 
results of both. For all persons in WA between 1988 - 2007, malignant melanoma 
represented approximately 10% of all diagnosed cancers in people with a psychiatric 
disorder (n 618 / 6586). 
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4.7.1 Baseline characteristics 
During this period there were 618 psychiatric patients in the inception cohort who had a 
diagnosis of malignant melanoma, 285 of whom were male (Table 4). There were 14,059 non 
psychiatric patients with melanoma. Both males and females were significantly less likely to 
be diagnosed as having a melanoma than the general population. There was little variation 
between psychiatric diagnoses although conclusions were limited by the small number of 
cases for some of the categories. The only disorders associated with increased incidence 
were Other Psychoses and Other Mental Disorders (both male and female) as well as 
Attempted Self Harm (females). Melanoma incidence in patients with schizophrenia was no 
higher than that of the general population, although the 95% confidence intervals were 
wide, reflecting the small number (24) of patients with schizophrenia who developed 
melanoma (Table 4). Some diagnoses were actually associated with increased melanoma 
risk: attempted self harm in females and other psychoses and other mental disorder in both 
males and females. There was no clear pattern with the other diagnoses, again possibly 
because of small numbers and wide confidence intervals. 
 
Psychiatric diagnosis 
Male Female
N RR 95% CI N RR 95% CI 
Dementia 37 0.87 (0.63 - 1.19) 52 0.90 (0.80 - 1.02) 
Alcohol/drug disorders 20 0.79 (0.51 - 1.21) 7 1.10 (0.78 - 1.54) 
Schizophrenia 12 0.90 (0.68 - 1.19) 12 1.21 (0.86 - 1.71) 
Affective psychosis 39 1.03 (0.79 - 1.35) 40 0.86 (0.63 - 1.19) 
Other psychoses 28 1.33 (1.05 - 1.69) 18 2.12 (1.71 - 2.63) 
Neurotic disorders 17 0.72 (0.43 - 1.19) 42 0.93 (0.66 - 1.29) 
Personality disorders 6 1.47 (0.93 - 2.32) 5 1.30 (0.91 - 1.86) 
Stress/Adjustment 
reaction 
37 0.83 (0.55 - 1.25) 48 0.86 (0.56 - 1.32) 
Depressive disorder 40 0.89 (0.63 - 1.25) 62 1.12 (0.90 - 1.39) 
Other mental disorder 28 1.35 (1.01 - 1.80) 13 1.44 (1.12 - 1.86) 
Attempted self-harm 5 1.38 (0.95 - 2.02) 5 2.24 (1.62 - 3.11) 
Non-specific diagnosis 16 1.05 (0.73 - 1.51) 29 1.14 (0.91 - 1.43) 
Total 285 0.72 (0.61 - 0.86) 333 0.84 (0.73 - 0.96) 
Table 4. Cancer Site - Malignant Melanoma, by principal psychiatric diagnosis. WA, 1988 – 
2007 (inception cohort). 
In both psychiatric patients and the general population, melanoma incidence rate increased 
with age. The rate was higher in males than in females, except in psychiatric patients 
between the ages of 35-55 years. The peak incidence for both the general population and 
psychiatric patients was between 75 – 85 years of age (Figure 4). 
In the case of the historical cohort, there were 1,166  psychiatric patients who had a 
diagnosis of malignant melanoma, 526  of whom were male (Table 5). On average, incidence 
rates using the historical cohort method were slightly lower than those calculated using the 
inception cohort approach. As in the inception cohort, males and females were significantly 
less likely to be diagnosed as having a melanoma. There was little variation between 
psychiatric diagnoses although conclusions were again limited by the small number of cases 
for some of the categories. As before, rates increased with age and the rate was higher in 
males than in females, except between the ages of 35-55 years (data not shown). 
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Fig. 4. Age-specific melanoma incidence rates, psychiatric patients versus WA population 
(inception cohort). 
With greater numbers (n=57), melanoma incidence in people with schizophrenia was 
significantly lower in both males (0.51 - 95% CI 0.29 - 0.92) and females (0.68 - 95% CI 0.46 - 
0.99). Again with more subjects and narrower confidence intervals,  melanoma incidence 
was also lower in dementia and affective psychoses in both sexes. They were lowest in 
males with alcohol and drug disorders. The only situation where incidence was higher than 
that of the general population was for  females who  attempted self harm (Table 5). 
 
Psychiatric diagnosis Male Female
N RR 95% CI N RR 95% CI 
Dementia 59 0.69 0.51 - 0.93 67 0.79 0.71 - 0.88 
Alcohol/drug disorders 36 0.49 0.29 - 0.82 16 0.78 0.52 - 1.18 
Schizophrenia 33 0.51 0.29 – 0.92 24 0.68 0.46 – 0.99 
Affective psychosis 67 0.71 0.51 – 0.99 88 0.68 0.50 – 0.93 
Other psychoses 44 0.81 0.58 – 1.15 29 1.08 0.70 – 1.67 
Neurotic disorders 48 0.76 0.54 – 1.06 83 0.78 0.58 – 1.04 
Personality disorders 19 0.98 0.67 – 1.44 15 0.91 0.60 – 1.38 
Stress/Adjustment 
reaction 
53 0.61 0.39 – 0.98 84 0.69 0.46 – 1.03 
Depressive disorder 68 0.68 0.48 – 0.95 135 0.90 0.74 – 1.09 
Other mental disorder 44 1.06 0.77 – 1.48 24 1.16 0.86 – 1.55 
Attempted self-harm 6 1.13 0.86 – 1.48 11 1.61 1.17 – 2.20 
Non-specific diagnosis 49 0.86 0.64 – 1.16 64 1.02 0.79 – 1.30 
Total 526 0.60 0.52 – 0.70 640 0.71 0.64 – 0.80 
Table 5. Cancer Site - Malignant Malignant Melanoma, by principal psychiatric diagnosis. 
WA, 1988 – 2007 (historical cohort). 
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4.7.2 Presence of metastases at baseline or follow-up 
50 inception cohort patients with primary melanoma had metastasised at time of original 
diagnosis as determined from the tumour behaviour code (8.1%) This was not significantly 
different from that of the general population (9.9% - p = 0.107).  
Ninety days later, 3 patients had developed metastases. Again there was no difference 
between psychiatric patients and the general population (0.5% and 0.6% p=0.771). By one 
year, 7 patients had developed metastases. As before, there was no difference between 
psychiatric patients and the general population (1.2% and 1.6% respectively P=0.332).  
For the historical cohort, 86 (7.4%) patients with an assigned primary melanoma had 
metastasised at time of original diagnosis as determined from the tumour behaviour code. 
This was slightly yet significantly different from the general population 9.9% p=0.002. 
Ninety days later, 7 patients had developed metastases. Again there was no difference 
between psychiatric patients and the general population (0.6% and 0.6% respectively 
p=0.720). By one year, 12 patients had developed metastases. As before, there was no 
difference between psychiatric patients and the general population (1.1% and 1.6% 
respectively p=0.157). 
4.7.3 Receipt of chemotherapy or radiotherapy and time to surgery 
We then investigated differences between psychiatric patients and the general population 
with regards access to surgery and receipt of chemotherapy and radiotherapy. 0.7% (n=4) of 
psychiatric patients received chemotherapy for their melanoma within 90 days of diagnosis 
compared with 1% of melanoma patients with no contact with MHS. This difference was not 
statistically significant (p=0.216, Table 6). A similar proportion of psychiatric patients and 
people from the general population received radiotherapy (p=0.196 Table 6). 
 
Procedure 
Cohort 
Inception
No contact with 
MHS 
Started chemotherapy within 90 days of cancer diagnosis 0.7% 1.0% 
Received radiotherapy 1.4% 2.1% 
Table 6. Receipt of chemotherapy and radiotherapy. 
We found similar results for the historical cohort (data not shown). 
Finally, we investigated time to surgical removal of tumour. In the inception cohort 126 
psychiatric patients with malignant melanoma received surgical intervention within 90 days 
of cancer diagnosis. There was no significant difference between psychiatric patients and the 
general population in time to surgery (Figure 5) (p=0.473). Again, we found similar results 
for the historical cohort (data not shown).  
4.7.4 Mortality in psychiatric patients with melanoma 
Using the inception cohort approach, 149 psychiatric patients with malignant melanoma 
died during the follow-up period. Of these deaths, 58 were coded as primary cause of death 
being malignant melanoma (Table 7). Of the 2,840 deaths during the follow-up period 
among malignant melanoma patients who had not had any prior contact with mental health 
services, 1,558 deaths were classified as malignant melanoma being the primary cause 
(Table 7).  
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Fig. 5. % of patients who accessed surgery up to 90 days after diagnosis of their melanoma, 
WA, 1988 – 2007. 
 
 Inception cohort Historical cohort 
Psychiatric 
case 
Non 
Psychiatric 
case 
Psychiatric 
case 
Non 
Psychiatric 
case 
All cause mortality 149 2840 263 2840 
All cause hazard ratio 1.81 (1.53 – 2.14) 1.67 (1.47 – 1.90) 
Cancer specific mortality 58 1558 118 1558 
Cancer specific hazard ratio 1.34 (1.03 – 1.74) 1.32 (1.10 – 1.60) 
Total patients with melanoma 618 14059 1166 14059 
Table 7. Mortality in Psychiatric Patients with Melanoma WA, 1988 – 2007. 
We compared the mortality rates between melanoma patients with and without a history of 
contact with mental health services using proportional hazards regression. This model 
allowed us to adjust for differences in the age and sex make-up of the two different cohorts. 
After adjusting for age, sex and socio-economic status (based on area of residence), 
psychiatric patients had a higher risk of all cause- and melanoma-specific mortality (Table 
7). The difference between these two rates indicates that melanoma patients with a history of 
contact with mental health services were more likely to die as a direct result of melanoma, 
and also more likely to die from other causes. After malignant melanoma itself, the most 
common cause of death among melanoma patients with a history of contact with mental 
health services was coronary heart disease. In common with our findings on cancer 
incidence, all-cause and cancer specific mortally were lower in the historical than in the 
inception cohort. However both were significantly greater than those of the general 
population. 
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5. Discussion 
There is literature on the adverse affect of depression on survival from melanoma. There is 
also literature on the incidence of melanoma in people with schizophrenia, and whether this 
is lower than that of the general population.35, 36 Lastly, there is limited literature comparing 
incidence and mortality in patients of specialist psychiatric services.17 To our knowledge, 
these  studies conducted in WA and QLD are the first  to investigate melanoma incidence 
and mortality rates in people with psychiatric disorder that include outpatient data, where 
the vast majority of people receive treatment. Our findings therefore give a fuller picture of 
the relationship between psychiatric disorder and melanoma. Another strength is the use of 
both inception and historical cohort data, exploiting the advantages of each. Historical 
cohorts may have greater statistical power because of increased numbers, but may 
underestimate mortality risk because of survivorship bias. Our findings of lower incidence 
and mortality rates in the historical as opposed to inception cohort would be consistent with 
this pattern. Inception cohorts may be more sensitive to the increased mortality risk faced by 
patients but be underpowered to detect  rarer outcomes. Again, this was suggested by our 
study where analysis of subgroups, such as schizophrenia only yielded significant results in 
our historical cohort.  
Our latest findings confirm our previous work on melanoma from Western Australia and 
Canada. With a further 10 years of data we found a continued pattern of an incidence that 
was lower, or no higher, than that of the general population alongside a mortality that was 
higher. This pattern is not unique to melanoma and has been identified for other cancers 
such as lung, colorectal, breast and prostate cancers even after adjusting for factors such as 
smoking.28 Studying melanoma has particular advantages as this site may be less affected by 
potential medication or lifestyle confounders such as diet or alcohol and substance use. 
Studies of cancers, such as colorectal and lung, can only control for known lifestyle 
confounders and, even then, it is not possible to adjust for all of these.28 By contrast, 
malignant melanoma is mainly related to childhood sun exposure,29 and there is no 
evidence of reduced childhood sun exposure in individuals who subsequently develop 
psychiatric disorder.28 As such, this cancer may be less subject to confounding by concurrent 
factors of lifestyle.  
As regards schizophrenia, our historical cohort  findings are consistent with a large meta-
analysis by Catts et al that reported significantly reduced standardised incidence ratios 
(SIRs) for malignant melanoma of 0.71 for patients with schizophrenia (CI 0.57–0.87; P = 
0.002).28 The absence of any significant reduction in our inception cohort may be partly 
explained by the low numbers (n=24). Our historical cohort results also suggest that this 
effect extends to other psychiatric diagnoses, which tends to militate against biological 
hypotheses of why people with schizophrenia might be protected against cancer in general. 
Biological explanations include a protective effect of excess dopamine, enhanced natural 
killer cell activity, increased  apoptosis, or modulation by antipsychotic drugs of cytochrome 
enzymes involved in mutagen activation and elimination, as well as the hypothesis of 
relative vitamin D deficiency.27 
If biological explanations may be less applicable to the pattern we observed for melanoma 
for people with all types of psychiatric disorder, other hypotheses merit consideration. One 
is that cancer is undiagnosed in people with psychiatric disorder. Reduced cancer incidence 
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rates in psychiatric disorder in general, and schizophrenia in particular, could  be due to 
lower detection rates related to poorer self-care and substandard preventive health care.28 
However, it has been argued that while medical comorbidity in general is under-recognized, 
this does not seem to apply to cancer in general.28  For instance, post-mortem data collected 
between 1966 and 1980 in Denmark, where the autopsy rates were in the order of 30–50% in 
both patients with schizophrenia and the general population, indicated that the post-
mortem diagnosis of previously unrecognized cancer was rare. It is unclear whether these 
findings would apply to melanoma because unlike cancers such as lung or colorectal cancer, 
there may be few obvious early symptoms.28  
Another explanation is that people with psychiatric disorder receive poorer care. Work from 
Ontario shows that other marginalised populations, such as those of low income, are less 
likely to receive specialist procedures such as adjuvant or palliative radiotherapy, even 
under universal health care.32 We have also shown that psychiatric patients are less likely to 
receive appropriate specialised procedures for cardiovascular disease in both Australia and 
Canada.17, 37 In the case of the former, one explanation might be that many of the procedures 
are carried out in the private health system for which people with many psychiatric 
disorders would be unable to find insurance. This would not apply to Canada, where the 
private health sector has no role in the provision of medically necessary procedures.  
It is possible that physicians are reluctant to offer some procedures because of the ensuing 
psychological stress, concerns about capacity or compliance with postoperative care, or the 
presence of contra-indications such as smoking. In addition, psychiatric patients may be 
more at risk of developing complications following medical or surgical interventions38 or to 
have poorer outcomes post-operatively.39  
So what do our latest results suggest about the role of under-diagnosis, delayed diagnosis or 
inequity in treatment? Our project could not address the first explanation as this would 
require a detailed investigation of death register or post-mortem records to ascertain the 
presence of melanoma at death that had not been previously treated. Our study does not 
particularly shed light on the other two explanations. Psychiatric patients in the historical 
cohort were significantly more likely to have metastases at time of original diagnosis 
(p=0.002). Otherwise, psychiatric patients were no more likely to present with metastases, or 
develop them 90 days or 1 year afterwards, than the general population. Neither were they 
less likely to receive specialised procedures such as radio- or chemotherapy.  
These findings would be consistent with work on cancer in general showing there is little 
evidence of delayed detection in people with psychiatric disorder such as schizophrenia.28 
However, as discussed in the following paragraph, this study may have been under-
powered to detect any difference in the presence of metastases, or of treatment access.  
5.1 Study limitations 
We used routinely collected administrative data to maximise coverage across the state, keep 
within budget and maximise statistical power. However reliance on secondary data meant 
that we were unable to collect information on quality of life. The WA cancer register does 
not contain information on staging other than the presence or absence of metastases. 
Administrative data may also be subject to recording bias, especially for diagnosis. Most 
data concerning the validity of our case–definition of treated psychiatric disorder are for 
overall morbidity rather than specific diagnoses. We have therefore emphasised overall 
psychiatric morbidity, not sub-categories, to minimise possible bias. We were unable to 
study the effects of lifestyle such as use of sunscreen and sun exposure. However, this 
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would not explain our finding of an increased risk of mortality in the presence of an 
incidence that was no higher than that of the general population. We were unable to 
separately study the relationship between specific psychiatric disorder and melanoma 
because of small numbers. In a similar vein, this study may have been under-powered to 
detect any difference in the presence of metastases, or of treatment access. Our results so far 
have been confined to Western Australia. The addition of Queensland data covering a 
population that is more than double that of Western Australia may address study power. In 
addition, the Queensland Cancer Registry has the advantage over Western Australia of 
collecting staging data on melanoma. Lastly, we were only able to capture data on access to 
surgery as well as admissions for radio- or chemotherapy, and so cannot comment on access 
to other interventions for melanoma. 
6. Conclusions  
This chapter has illustrated some of the complex interactions between melanoma and 
psychiatric disorder. It extends our previous work with another decade of Australian data to 
further explore these relationships through to 2007. These findings provide further evidence 
of a melanoma incidence in psychiatric patients that was lower or no higher than that of the 
general population alongside a mortality that was higher. Furthermore, this pattern extends 
to a broad range of psychiatric disorders and not just schizophrenia, where the low 
incidence of melanoma was first described. Although we were unable to show any clear 
reason in terms of delays in presentation as shown by metastases, or of access to treatment, 
the availability of just West Australian data may have meant the study was underpowered. 
The addition of Queensland data may rectify this. More research is certainly needed on why 
psychiatric patients with melanoma are more likely to die of the condition, but no more 
likely to develop it in the first place. This has implications for both primary and secondary 
care, including access to appropriate treatment for psychiatric patients with melanoma, as 
well as of awareness of the psychiatric symptoms of treatments for melanoma. 
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